On June 5, 2024 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") reported the grant of European Patent No. 4269578, covering the ENHANZE rHuPH20 product obtained from Halozyme’s ENHANZE manufacturing methods that the Company provides to its current and future licensees (Press release, Halozyme, JUN 5, 2024, View Source [SID1234644144]). The new patent is licensed under all of Halozyme’s ENHANZE licenses. It will be validated in 37 European countries and expires on March 6, 2029.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This new European patent for ENHANZE further strengthens our robust patent estate and extends the durability of our portfolio," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We are pleased to be able to maintain the original royalty rate for DARZALEX SC in Europe through March 2029 based on this new patent."

Under the terms of Halozyme’s ENHANZE license with Janssen, the newly granted patent prevents the reduction in the royalty rate on sales of DARZALEX SC in the European countries where it is validated until the patent expires. The new patent is not expected to have any impact to royalties under other ENHANZE licenses with an issued or pending collaboration patent, as current royalty rates for these licenses are already expected to extend beyond expiration of the new patent.

Webcast and Conference Call

Halozyme will discuss the new European patent and provide an update to its 2024 financial guidance and 5-year financial outlook on a conference call tomorrow, Thursday, June 6 at 5:30am PT/8:30am ET. The call will be webcast live through the "Investors" section of Halozyme’s corporate website and a recording will be made available following the completion of the call. To access the webcast and presentation, please visit ir.halozyme.com.

The call may also be accessed with the dial-in information below:

Participant Toll-Free Number: 888-632-3384
Participant Direct/International Number: 785-424-1794
Conference ID: HALO0624